BACKGROUND Often the clinician is faced with a diagnostic and therapeutic dilemma in patients with concomitant traumatic brain injury (TBI) and hemorrhagic shock (HS), as rapid deterioration from either can be fatal. Knowledge about outcomes after concomitant TBI and HS may help prioritize the emergent management of these patients. We hypothesized that patients with concomitant TBI and HS (TBI + HS) had worse outcomes and required more intensive care compared with patients with only one of these injuries. METHODS This is a post hoc analysis of the Pragmatic, Randomized Optimal Platelets and Plasma Ratios (PROPPR) trial. TBI was defined by a head Abbreviated Injury Scale score greater than 2. HS was defined as a base excess of −4 or less and/or shock index of 0.9 or greater. The primary outcome for this analysis was mortality at 30 days. Logistic regression, using generalized estimating equations, was used to model categorical outcomes. RESULTS Six hundred seventy patients were included. Patients with TBI + HS had significantly higher lactate (median, 6.3; interquartile range, 4.7–9.2) compared with the TBI group (median, 3.3; interquartile range, 2.3–4). TBI + HS patients had higher activated prothrombin times and lower platelet counts. Unadjusted mortality was higher in the TBI + HS (51.6%) and TBI (50%) groups compared with the HS (17.5%) and neither group (7.7%). Adjusted odds of death in the TBI and TBI + HS groups were 8.2 (95% confidence interval, 3.4–19.5) and 10.6 (95% confidence interval, 4.8–23.2) times higher, respectively. Ventilator, intensive care unit–free and hospital-free days were lower in the TBI and TBI + HS groups compared with the other groups. Patients with TBI + HS or TBI had significantly greater odds of developing a respiratory complication compared with the neither group. CONCLUSION The addition of TBI to HS is associated with worse coagulopathy before resuscitation and increased mortality. When controlling for multiple known confounders, the diagnosis of TBI alone or TBI+HS was associated with significantly greater odds of developing respiratory complications. LEVEL OF EVIDENCE Prognostic study, level II.
from ! ORL Sfakianakis via paythelady.61 on Inoreader http://ift.tt/2xsl61X
via IFTTT
Medicine by Alexandros G. Sfakianakis,Anapafseos 5 Agios Nikolaos 72100 Crete Greece,00302841026182,00306932607174,alsfakia@gmail.com,
Αρχειοθήκη ιστολογίου
-
►
2023
(272)
- ► Φεβρουαρίου (141)
- ► Ιανουαρίου (131)
-
►
2022
(2066)
- ► Δεκεμβρίου (80)
- ► Σεπτεμβρίου (170)
- ► Φεβρουαρίου (190)
- ► Ιανουαρίου (203)
-
►
2021
(7399)
- ► Δεκεμβρίου (186)
- ► Σεπτεμβρίου (472)
- ► Φεβρουαρίου (851)
-
►
2020
(2517)
- ► Δεκεμβρίου (792)
- ► Σεπτεμβρίου (21)
- ► Φεβρουαρίου (28)
-
►
2019
(12076)
- ► Δεκεμβρίου (19)
- ► Σεπτεμβρίου (54)
- ► Φεβρουαρίου (4765)
- ► Ιανουαρίου (5155)
-
►
2018
(3144)
- ► Δεκεμβρίου (3144)
-
▼
2017
(66935)
-
▼
Δεκεμβρίου
(1995)
-
▼
Δεκ 03
(11)
- How to Stop or Prevent Ceramic Braces from Staining
- Weekly Top Insider Buys Highlight for the Week of ...
- Mucositis in adult cancer patients reduced with ke...
- The applications of regenerative medicine in sinus...
- New year-round dentists opens in Leicester - and f...
- Officials Suspend License of Delaware Dentist, Nurse
- Machine Learning for Fetal Growth Prediction
- RAM of Virginia brings army of volunteers to Warsaw
- Outcomes after concomitant traumatic brain injury ...
- A.R. Chesson building new office for dental practice
- Lowell dentists irked by plan to take office land ...
-
▼
Δεκ 03
(11)
- ► Σεπτεμβρίου (12424)
-
▼
Δεκεμβρίου
(1995)
Ετικέτες
Πληροφορίες
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Αναζήτηση αυτού του ιστολογίου
! # Ola via Alexandros G.Sfakianakis on Inoreader
-
Publication date: 1 May 2019 Source: Talanta, Volume 196 Author(s): Ruiqing Long, Te Li, Chaoying Tong, Lihui Wu, Shuyun Shi Abstract...
-
Oral Cancer Rapid Test Kit Market Rugged Expansion Foreseen by 2024 MilTech Oral cancer is one of the largest group of cancers ...
-
Related Articles SRPK1 maintains acute myeloid leukemia through effects on isoform usage of epigenetic regulators including BRD4...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου
Medicine by Alexandros G. Sfakianakis,Anapafseos 5 Agios Nikolaos 72100 Crete Greece,00302841026182,00306932607174,alsfakia@gmail.com,